Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Novartis ( (NVS) ).
On November 5, 2025, Novartis AG announced the issuance of several debt securities through its subsidiary, Novartis Capital Corporation, amounting to a total of $6 billion. These securities include Floating Rate Notes and various fixed-rate notes with maturities ranging from 2028 to 2055. The move is part of Novartis’s strategy to secure funding for its operations and investments, potentially impacting its financial flexibility and market positioning.
The most recent analyst rating on (NVS) stock is a Buy with a $138.00 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.
Spark’s Take on NVS Stock
According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.
Novartis’s strong financial performance and positive earnings call are the primary drivers of its overall score. However, bearish technical indicators and a fair valuation slightly temper the outlook. The company’s strategic focus on innovation and expansion supports long-term growth prospects.
To see Spark’s full report on NVS stock, click here.
More about Novartis
Novartis AG is a leading global healthcare company based in Switzerland, primarily engaged in the research, development, manufacturing, and marketing of a wide range of healthcare products. The company focuses on innovative medicines, generics, and eye care products, aiming to improve patient outcomes and healthcare accessibility worldwide.
Average Trading Volume: 1,460,462
Technical Sentiment Signal: Buy
Current Market Cap: $238.8B
See more data about NVS stock on TipRanks’ Stock Analysis page.